Method of DNA vaccinationA method of vaccinating a mammal against a disease state, comprising administrating to said mammal, within an appropriate vector, a nucleotide sequence encoding an antigenic peptide associated with the disease state; additionally administering to said mammal a compound which enhances both humoral and cellular immune responses initiated by the antigenic peptide, the compound being selected from the list contained herein,  wherein the compound is preferably Tucaresol or a physiologically acceptable salt or ester thereof, where appropriate.Seeded with mammalian is in case the method for morbid state comprises the nucleotide sequence that gives the coding of described mammal in the suitable carrier antigenic peptides relevant with described morbid state;give described mammal in addition and strengthen the body fluid that excited by antigenic peptides and the chemical compound of cellullar immunologic response, described chemical compound is selected from: 4-(2-formyl-3-hydroxyl phenoxymethyl) benzoic acid; 5-(2-formyl-3-hydroxyphenoxy) pentanamide; n, n-diethyl 5-(2-formyl-3-hydroxyphenoxy) pentanamide; n-isopropyl 5-(2-formyl-3-hydroxyphenoxy) pentanamide; 5-(2-formyl-3-hydroxyphenoxy) ethyl valerate; 5-(2-formyl-3-hydroxyphenoxy) valeronitrile; (±)-5-(2-formyl-3-hydroxyphenoxy)-2 methyl valeric acid; 5-(2-formyl-3-hydroxyphenoxy)-2,2-dimethyl valeric acid; 3-(2-formyl-3-hydroxyphenoxy) methyl toluate; 3-(2-formyl-3-hydroxyphenoxy) ar-toluic acid; 5-(2-formyl-3-hydroxyphenoxy) benzyl valerianate; 5-[4-(2-formyl-3-hydroxyphenoxy)-n-butyl] tetrazolium; 7-(2-formyl-3-hydroxyphenoxy) enanthic acid; 5-(2-formyl-3-hydroxyl-4-positive propoxy phenoxy group) valeric acid; 5-(4,6-two chloro-2-formyl-3-hydroxyphenoxies) valeric acid; 5-(2-formyl-3-hydroxyphenoxy)-n-sulfonyloxy methyl pentanamide; 4-(2-formyl-3-hydroxyl phenoxymethyl) ethyl benzoate; 5-(4-chloro-2-formyl-3-hydroxyphenoxy) valeric acid; 5-(3-acetylaminohydroxyphenylarsonic acid 2-formyl phenoxy group) valeric acid; aminoguanidine; 4-(2-formyl-3-hydroxyphenoxy) butanoic acid; 6-(2-formyl-3-hydroxyphenoxy) caproic acid; 4-(3-acetylaminohydroxyphenylarsonic acid 2-formyl phenoxymethyl) ethyl benzoate; 4-(3-acetylaminohydroxyphenylarsonic acid 2-formyl phenoxymethyl) benzoic acid; 2-(2-formyl-3-hydroxyl phenoxymethyl) benzoic acid; 5-[4-(2-formyl-3-hydroxyl phenoxymethyl) phenyl] tetrazolium; 5-(2-formyl-3-hydroxyl-4-methoxyl group phenoxy group) valeric acid; 3-(2-formyl-3-hydroxyphenoxy) propionitrile; 4-hydroxy benzenes acetaldehyde; hyacinthin; 4-methoxybenzene acetaldehyde; 1-hydroxyl-2-phenyl-propane; 3-hydrocinnamicaldehyde (proponionaldeyde); the 4-nitrobenzaldehyde; 4-carbamoyl benzoate methyl ester; the 4-chlorobenzaldehyde; the 4-methoxybenzaldehyde; the 4-tolyl aldehyde; 8,10-dioxo undecanoic acid; 4,6-dioxo enanthic acid; pentanedione; 5-methoxyl group-1-1,2,3,4-tetrahydrooxonaphthalene; 6-methoxyl group-1-1,2,3,4-tetrahydrooxonaphthalene; 7-methoxyl group-1-1,2,3,4-tetrahydrooxonaphthalene; the 2-1,2,3,4-tetrahydrooxonaphthalene; 3-hydroxyl-1-(4-methoxyphenyl)-3-methyl-2-butanone; 2 ', 4 '-dihydroxy-2-(4-methoxyphenyl) acetophenone; 2-hydroxyl-1-(4-methoxyphenyl)-penta 2 alkene-4 ketone; naringenin 4 ', 5,6-trihydroxyflavone (flavonone); 4 '-methoxyl group-2-(4-methoxyphenyl) acetophenone; 6, the 7-dihydroxycoumarin; 7-methoxyl group-2-1,2,3,4-tetrahydrooxonaphthalene; 6,7-dimethoxy-2-1,2,3,4-tetrahydrooxonaphthalene; the 6-hydroxy-4-methylcoumarin; the 2,5-dihydroxy-.alpha.-toluic acid. gamma lactone; 6-hydroxyl-1, the 2-naphthoquinone; 8-methoxyl group-2-1,2,3,4-tetrahydrooxonaphthalene; and suitable physiological acceptable salt.
ＤＮＡ 접종 방법본 발명은 질병 상태와 관련된 항원성 펩티드를 코딩하는 뉴클레오티드 서열을 적절한 벡터에 삽입하여 포유동물에게 투여하고, 상기 항원성 펩티드에 의해 유발되는 체액성 및 세포성 면역 반응을 둘다 증강시키는 화합물을 추가 투여하는, 상기 질병 상태를 억제하는 포유동물의 접종 방법에 관한 것이다. 상기 화합물은 명세서에 열거되어 있으며, 바람직하게는 투카레졸 및 적절하다면 이의 생리적으로 허용가능한 염 또는 에스테르이다.질병 상태와 관련된 항원성 펩티드를 코딩하는 뉴클레오티드 서열을 적절한 벡터에 삽입하여 포유동물에게 투여하고, 추가로, 상기 항원성 펩티드에 의해 유발되는 체액성 및 세포성 면역 반응을 둘다 증강시키는 4-(2-포르밀-3-히드록시페녹시메틸)벤조산, 5-(2-포르밀-3-히드록시페녹시)펜탄아미드, N,N-디에틸 5-(2-포르밀-3-히드록시페녹시)펜탄아미드, N-이소프로필 5-(2-포르밀-3-히드록시페녹시)펜탄아미드, 에틸 5-(2-포르밀-3-히드록시페녹시)펜타노에이트, 5-(2-포르밀-3-히드록시페녹시)펜타노니트릴, (±)-5-(2-포르밀-3-히드록시페녹시)-2-메틸펜탄산, 5-(2-포르밀-3-히드록시페녹시)-2,2-디메틸펜탄산, 메틸 3-(2-포르밀-3-히드록시페녹시)메틸벤조에이트, 3-(2-포르밀-3-히드록시페녹시)메틸벤조산, 벤질 5-(2-포르밀-3-히드록시페녹시)펜타노에이트, 5-[4-(2-포르밀-3-히드록시페녹시)-N-부틸]테트라졸, 7-(2-포르밀-3-히드록시페녹시)헵탄산, 5-(2-포르밀-3-히드록시-4-n-프로폭시페녹시)펜탄산, 5-(4,6-디클로로-2-포르밀-3-히드록시페녹시)펜탄산, 5-(2-포르밀-3-히드록시페녹시)-N-메틸술포닐펜탄아미드, 에틸 4-(2-포르밀-3-히드록시페녹시메틸)벤조에이트, 5-(4-클로로-2-포르밀-3-히드록시페녹시)펜탄산, 5-(3-아세틸아미노-2-포르밀페녹시)펜탄산, 아미노구아니딘, 4-(2-포르밀-3-히드록시페녹시)부탄산, 6-(2-포르밀-3-히드록시페녹시)헥산산, 에틸 4-(3-아세틸아미노-2-포르밀페녹시메틸)벤조에이트, 4-(3-아세틸아미노-2-포르밀페녹시메틸)벤조산, 2-(2-포르밀-3-히드록시페녹시메틸)벤조산, 5-[4-(2-포르밀-3-히드록시페녹시메틸)페닐]테트라졸, 5-(2-포르밀-3-히드록시-4-메톡시페녹시)펜탄산, 3-(2-포르밀-3-히드록시페녹시)프로피오니트릴, 4-히드록시페닐아세트알데히드, 페닐아세트알데히드, 4-메톡시페닐아세트알데히드, 1-히드록시-2-페닐프로판, 3-페닐프로피온알데히드, 4-니트로벤즈알데히드, 메틸 4-포르밀벤조에이트, 4-클로로벤즈알데히드, 4-메틸옥시벤즈알데히드, 4-메틸벤즈알데히드, 8,10-디옥소운데칸산, 4,6-디옥소헵탄산, 펜탄디온, 5-메톡시-1-테트랄론, 6-메톡시-1-테트랄론, 7-메톡시-1-테트랄론, 2-테트랄론, 3-히드록시-1-(4-메톡시페닐)-3-메틸-2-부타논, 2',4'-디히드록시-2-(4-메톡시페닐)아세토페논, 2-히드록시-1-(4-메톡시페닐)-펜트-2-엔-4-온, 나링게닌 4',5,6-트리히드록시플라보논, 4'-메톡시-2-(4-메톡시페닐)아세토페톤, 6,7-디히드록시쿠마린, 7-메톡시-2-테트랄론, 6,7-디메톡시-2-테트랄론, 6-히드록시-4-메틸쿠마린, 호모겐티신산 감마 락톤, 6-히드록시-1,2-나프토퀴논, 및 8-메톡시-2-테트랄론 중에서 선택된 화합물 및 적절하다면 생리적으로 허용가능한 이의 염을 상기 포유동물에게 투여하는 것을 포함하는, 질병 상태에 대한 포유동물의 접종 방법.